Comfrey

Comfrey works primarily through allantoin, a compound that stimulates cell proliferation and accelerates tissue regeneration. Allantoin promotes keratinocyte growth and connective tissue repair, while rosmarinic acid provides anti-inflammatory effects. The mucilage content forms a protective barrier over damaged tissue. This combination makes comfrey effective for wound healing, bone fractures, sprains, and bruises. Evidence level: B, supported by clinical trials and over 2,000 years of traditional use as 'knitbone.'

No, comfrey is unsafe during pregnancy and should be strictly avoided. The pyrrolizidine alkaloids (PAs) in comfrey are hepatotoxic and can cross the placental barrier, potentially causing liver damage to both mother and fetus. These compounds have been linked to veno-occlusive disease and carcinogenic effects. No safe threshold for PA exposure during pregnancy has been established. Breastfeeding women should also avoid comfrey in all forms. Evidence level: B for hepatotoxicity concerns.

Topical comfrey has minimal documented drug interactions, but caution is warranted with hepatotoxic medications. Because pyrrolizidine alkaloids can be absorbed through skin and cause liver stress, avoid combining comfrey with drugs like acetaminophen, isoniazid, methotrexate, or other liver-metabolized medications. Internal use is absolutely contraindicated with any medication due to cumulative hepatotoxicity risk. Patients with liver disease should avoid comfrey entirely. Always consult a healthcare provider before combining herbal treatments with prescription drugs.

Apply comfrey cream or ointment 2-3 times daily to intact, unbroken skin over the affected area. Treatment should not exceed 6 weeks of continuous use to minimize systemic absorption of pyrrolizidine alkaloids. Use only on closed injuries like sprains, bruises, or unbroken skin over fractures—never on open wounds. A thin layer is sufficient. Discontinue if no improvement occurs after 2 weeks. Evidence level: B for topical use in musculoskeletal injuries.

Comfrey contains pyrrolizidine alkaloids (PAs), which are hepatotoxic and potentially carcinogenic. Internal ingestion can cause hepatic veno-occlusive disease, where liver veins become blocked, potentially leading to liver failure. PAs are not destroyed by cooking or drying. Regulatory agencies including the FDA and EFSA have banned internal use of comfrey products. Topical application on intact skin is considered safer due to minimal systemic absorption, though prolonged use should still be avoided.